Navigation Links
Sangamo BioSciences to Present at Two Upcoming Investor Conferences
Date:9/29/2008

RICHMOND, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 11:30 a.m. (ET) on Monday, October 6, 2008, at the 2008 JMP Securities Healthcare Focus Conference and at 8:40 a.m. (ET) on Tuesday, October 7, 2008 at the William Blair Small Cap Conference. Both conferences are being held in New York City.

The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentations will be archived on the Sangamo website for two weeks after the events.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo i
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
2. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
3. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
4. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
5. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
6. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
7. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
8. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
9. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
10. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
11. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...re/--HealthRoboticstodayannounced,thatithasformeda...ors.ThisrecentlyformedToronto-basedcompanywilloper...rket,install,andsupport,HealthRobotics,i.v.Roomoft...uctofferingsi.v.STATION(TM),i.v.SOFT(TM),andOMM(TM...ceonan"asneeded,basis"toitsstrategicpartnershipswi...
(Date:11/24/2009)...Call/--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTI...HealthCareConference.TheconferencewillbeheldDecemb...resentonTuesday,December1at11:00a.m.EasternTimeinH...ionwillbeavailableat www.celltherapeutics.com ,and...rJaffrayHealthCareConference,NewYorkPalaceHotel,Ho...
(Date:11/23/2009)... communication, computation and more powerful ways...se quantum states as carriers of information is an...ave shown, mathematically, how to gently tease out...eping the information intact. Their work is report...s and highlighted with a Viewpoint in Physics (...
(Date:11/23/2009)...e-FirstCall/-YMBioSciencesInc.(NYSEAmex: YMI ;TSX:...tifiesandadvancesadiverseportfolioofpromisingcance...yreportedthatCytopia(ASX:CYT)hascommencedenrollmen...administeredJAK1/JAK2inhibitor.Thetrialisbeingcond...mergeCytopiaintoYMhasbeenpreviouslyannouncedandisp...
Breaking Biology Technology:Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...R, Mich., Feb. 18 NanoBio Corp., a,biopharmaceuti...ti-infective,treatments and intranasal vaccines, a... series B equity financing with Perseus LLC and ot...in funding has been directed toward the,developmen...m. , The series B funding will be used by the ...
...lif., Feb. 18 A new clinical study published this...ports that high-quality patient outcomes for breas...ity hospital setting. This is one of the few and t...arly relevant given that nearly two-thirds of all ...eated at community centers. , , The study tracked...
..., Feb. 18 Pharmos Corporation (Nasdaq: PARS ) a...nt with an Israel based company, Reperio Pharmaceu...ights and technical know how related to the compou...es. These CB2-selective cannabinoids are synthetic...al cannabinoids and thus display fewer of the unde...
Other Biology Technology:NanoBio Corporation Raises $12 Million in Series B Financing 2New Study Reports Improved Patient Outcomes for Breast Cancer Patients 2New Study Reports Improved Patient Outcomes for Breast Cancer Patients 3Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists 2Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists 3
(Date:11/23/2009)...INNATINew research presents strong evidence that t...both outdoor traffic-related pollution and indoor ...n one or the other exposure alone. , Environme...nati (UC) College of Medicine have shown that chil...d particles and indoor endotoxin during early life...
(Date:11/23/2009)...new study by the Wildlife Conservation Society say...swamp in the Republic of Congopart of the "mother ...t yearare becoming increasingly threatened by grow...ecommends protection of the swamp forests adjacent...ve after recent surveys confirmed that high densit...
(Date:11/23/2009)...ES, Iowa - The only swine vaccine available for th...rd infected with the virus. The vaccination marks ...rd diagnosed with the pandemic flu., Iowa State ...nce, developed the vaccine this summer and has bee...Iowa, Kansas and Illinois for several weeks., Th...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2DC 3A Muslim Coalition to Host Interfaith Hearing on Health Care 59326 1DC 3A Muslim Coalition to Host Interfaith Hearing on Health Care 59326 2Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt 28TM 29 an FDA Approved Oral Therapy for Schizophrenia 5408 1Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt 28TM 29 an FDA Approved Oral Therapy for Schizophrenia 5408 2Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt 28TM 29 an FDA Approved Oral Therapy for Schizophrenia 5408 3Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt 28TM 29 an FDA Approved Oral Therapy for Schizophrenia 5408 4Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt 28TM 29 an FDA Approved Oral Therapy for Schizophrenia 5408 5Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt 28TM 29 an FDA Approved Oral Therapy for Schizophrenia 5408 6Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt 28TM 29 an FDA Approved Oral Therapy for Schizophrenia 5408 7Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt 28TM 29 an FDA Approved Oral Therapy for Schizophrenia 5408 8Guardian Provides 100 25 Coverage For Swine Flu Vaccine 59321 1Guardian Provides 100 25 Coverage For Swine Flu Vaccine 59321 2
...ian islands of Borneo and Sumatra, scientists from... found what they say is the first demonstration in...ailable food supplies and brain size. , Based on t...ans confined to part of Borneo where food supplies...the process of natural selection comparatively sma...
...d most their contemporaries were not wiped out by ...paleontologist who says multiple meteor impacts, m...minated in the end of the Cretaceous Period. , Th...ser and earlier of a series of meteors and volcani...an 500,000 years, say Princeton University paleont...
...response to an avian influenza vaccine with doses ...a chemical mixture known as MF59. The research is ...ctious Diseases, now available online. , MF 59 i...ne system,s ability to respond to a stimulus. For ...H9N2 influenza vaccines--not the H5N1 virus curren...
Other Biology News:Study suggests evolutionary link between diet, brain size in orangutans 2Study suggests evolutionary link between diet, brain size in orangutans 3Study suggests evolutionary link between diet, brain size in orangutans 4'Fruit fly dating game' provides clues to our reproductive prowess 2'Fruit fly dating game' provides clues to our reproductive prowess 3
DHFR-1 FP-1 Forward Sequencing Primer from EPICENTRE Biotechnologies
Human Mesenchymal Stem Cell Functional Identification Kit from R&D Systems
Rabbit Anti-Syntrophin alpha 1 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Human HLA Class 1 A25 Monoclonal Antibody, Unconjugated, Clone 4i97 from Abcam
Biology Products: